Cullinan Oncology, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 57.96 million compared to USD 12.1 million a year ago. Basic loss per share from continuing operations was USD 1.42 compared to USD 0.27 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.72 USD | -5.55% | -1.35% | +172.03% |
29/04 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
29/04 | Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+172.03% | 1.26B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023